ArticleThe Journal of pharmacology and experimental therapeutics2011
Docosahexanoic acid-induced coronary arterial dilation: actions of 17S-hydroxy docosahexanoic acid on K+ channel activity.
Article in The Journal of pharmacology and experimental therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Potassium channels in vascular smooth muscle cells.Physiological reviews · 2026Review
- Oxylipin composition of high-density lipoprotein is altered in men and Hispanic adults with mild cognitive impairment.Journal of lipid research · 2026Article
- Suxiao Jiuxin Pill attenuates acute myocardial ischemia via regulation of coronary artery tone.Frontiers in pharmacology · 2023Article
- Omega-3 Polyunsaturated Fatty Acids-Vascular and Cardiac Effects on the Cellular and Molecular Level (Narrative Review).International journal of molecular sciences · 2022Review
- Myocardial Ischemia and Diabetes Mellitus: Role of Oxidative Stress in the Connection between Cardiac Metabolism and Coronary Blood Flow.Journal of diabetes research · 2019Review
- Retinal Pigment Epithelium and Photoreceptor Preconditioning Protection Requires Docosanoid Signaling.Cellular and molecular neurobiology · 2018Article
- Characterisation of the vasodilation effects of DHA and EPA, n-3 PUFAs (fish oils), in rat aorta and mesenteric resistance arteries.PloS one · 2018Article
- NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury.Journal of lipid research · 2017Article
- Overexcited MaxiK and KScientific reports · 2016Article
- Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.Advances in nutrition (Bethesda, Md.) · 2015Review
- Selective and potent inhibitory effect of docosahexaenoic acid (DHA) on U46619-induced contraction in rat aorta.Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi · 2013Article
- Mice lacking macrophage 12/15-lipoxygenase are resistant to experimental hypertension.American journal of physiology. Heart and circulatory physiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Despite extensive studies, the mechanisms mediating the cardiovascular actions of ω-3 polyunsaturated fatty acids has not yet been fully understood. The present study determined the possible actions of an endothelium-derived lipoxygenase product of docosahexanoic acid (DHA), 17S-hydroxy DHA (17S-HDHA), in bovine coronary arteries. High-performance liquid chromatography (LC) analysis demonstrated that bovine coronary arterial endothelial cells can metabolize DHA via lipoxygenases, and one of the major products was confirmed to be 17S-HDHA by LC-tandem mass spectrometry. In isolated perfused small bovine coronary arteries, 17S-HDHA (10⁻⁹ to 10⁻⁵ M) caused a concentration-dependent dilation with a maximum dilator response of 87.8 ± 2.5%, which is much more potent than the dilator response of its precursor, DHA. Moreover, 17S-HDHA-induced vasodilatations were significantly blocked by iberiotoxin, a large conductance Ca²(+)-activated K(+) (BK(Ca)) channel blocker, but not altered by an ATP-sensitive K(+) channel blocker, glibenclamide. In patch-clamp whole-cell recording, 17S-HDHA markedly increased K(+) currents in coronary arterial smooth muscle cells. In the inside-out mode, but not in the cell-attached mode, 17S-HDHA dramatically increased the BK(Ca) channel activity, which was substantially blocked by iberiotoxin. Collectively, our findings indicate that 17S-HDHA, an endothelium-derived DHA product via lipoxygenase, activates BK(Ca) channels in coronary arterial smooth muscle cells, leading to coronary vasodilation, which may represent an important mechanism mediating the beneficial actions of DHA in coronary circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.